2012 Antigen Review for the New Zealand National Immunisation Schedule: Pertussis

Show simple item record

dc.contributor.author Petousis-Harris, Helen en
dc.contributor.author Turner, Nicola en
dc.contributor.author Ellis, Tracey en
dc.contributor.author Nowlan, Mary en
dc.date.accessioned 2019-09-15T20:51:53Z en
dc.date.issued 2014-07 en
dc.identifier.citation Jul 2014. Auckland UniServices Limited, Auckland, New Zealand. 65 pages en
dc.identifier.uri http://hdl.handle.net/2292/47710 en
dc.description.abstract Despite widespread gains in disease control with vaccination programmes, pertussis remains a major global public health problem. Pertussis is a disease that occurs across the age spectrum. Young infants remain at risk of serious disease which continues to cause fatalities in both developed and developing countries. The primary focus of pertussis vaccination policy internationally is to reduce the risk of severe pertussis in infants. This requires both a complete and timely delivery of the primary immunisation series and the appropriate use of booster doses of pertussis vaccine. The worldwide priority is to achieve greater than 90 per cent coverage for the primary infant series of three doses with a high quality pertussis vaccine in infants. Universal implementation of infant immunisation has reduced the number of infant deaths and the incidence of pertussis disease in younger children. The contribution that older age groups make to the spread of pertussis to infants has been increasingly recognised in recent decades and has become a key consideration in contemporary refinements of national and international immunisation recommendations. Whole-cell pertussis vaccines have been in use since the 1940s. Their effectiveness is shown by the 150 to 200 fold decrease in incidence rate of pertussis seen in the United States between the 1940s and the 1970s. While effective, they are among the more reactogenic of vaccines and have never been considered appropriate for use in older children and adults. Since the 1990s many countries have moved to using acellular pertussis vaccines which have better reactogenicity profiles than whole cell pertussis vaccines and can be used across the age range. The most efficacious acellular vaccines are, at best, only as efficacious as the most efficacious whole-cell vaccines. Duration of vaccine induced immunity from acellular pertussis vaccines appears to be shorter than what was achieved when immunisation schedules consisted solely of whole-cell vaccines. There is considerable concern that immunisation schedules which consist solely of acellular pertussis vaccine are less effective at controlling pertussis than were whole cell vaccine schedules. Natural immunity to pertussis is incomplete and hence pertussis is a recurrent disease in humans. Our incomplete understanding of the pathogenesis and immunology of Bordetella pertussis infection and pertussis disease continues to limit our capacity to develop vaccines that provide sustained protection against disease or effective prevention of transmission of B. pertussis. en
dc.description.uri http://www.thebookshelf.auckland.ac.nz/document.php?action=null&wid=2957 en
dc.publisher Auckland UniServices Limited en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title 2012 Antigen Review for the New Zealand National Immunisation Schedule: Pertussis en
dc.type Report en
dc.rights.holder Copyright: Immunisation Advisory Centre, University of Auckland en
pubs.author-url https://www.immune.org.nz/2012-antigen-review-new-zealand-national-immunisation-schedule-pertussis en
pubs.commissioning-body New Zealand Ministry of Health en
pubs.place-of-publication Auckland, New Zealand en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Commissioned Report en
pubs.elements-id 424607 en
dc.relation.isnodouble 1385438 *
dc.relation.isnodouble 1385425 *
dc.relation.isnodouble 1385427 *
dc.relation.isnodouble 1385420 *
dc.relation.isnodouble 1385423 *
dc.relation.isnodouble 1385417 *
dc.relation.isnodouble 1385422 *
dc.relation.isnodouble 1385433 *
dc.relation.isnodouble 1385435 *
dc.relation.isnodouble 1385437 *
dc.relation.isnodouble 1385429 *
dc.relation.isnodouble 1385431 *
dc.relation.isnodouble 1385428 *
pubs.org-id Medical and Health Sciences en
pubs.org-id Population Health en
pubs.org-id Gen.Practice& Primary Hlthcare en
pubs.record-created-at-source-date 2014-01-23 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace